Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

The value of serum thyreoglobulin levels and whole body (I-131) scintigraphy in the follow-up of the thyroid cancer patients after thyroidectomy.

Kucukalić-Selimović E, Alagić J, Valjevac A, Hadzović-Dzuvo A, Begić A, Beslić N.

Coll Antropol. 2012 Nov;36 Suppl 2:67-71.

PMID:
23397758
2.

Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.

de Geus-Oei LF, Oei HY, Hennemann G, Krenning EP.

Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):768-74. Epub 2002 Mar 13.

PMID:
12029550
3.

The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer.

Roelants V, Nayer PD, Bouckaert A, Beckers C.

Eur J Nucl Med. 1997 Jul;24(7):722-7.

PMID:
9211756
4.

Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.

Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC, Hong SJ, Shong YK.

J Clin Endocrinol Metab. 2005 Mar;90(3):1440-5. Epub 2004 Dec 21.

PMID:
15613412
5.

Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.

Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D'Amico D, Della Morte AM, Pace L, Salvatore M.

Q J Nucl Med Mol Imaging. 2008 Mar;52(1):2-8.

9.

Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer.

Torlontano M, Crocetti U, D'Aloiso L, Bonfitto N, Di Giorgio A, Modoni S, Valle G, Frusciante V, Bisceglia M, Filetti S, Schlumberger M, Trischitta V.

Eur J Endocrinol. 2003 Jan;148(1):19-24.

10.

Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.

Pachón-Garrudo VM, Cuenca-Cuenca JI, Ruiz-Franco-Baux J, Borrego-Dorado I, Tirado-Hospital JL, Navarro-González E, Vázquez-Albertino R.

Rev Esp Med Nucl Imagen Mol. 2012 Nov-Dec;31(6):315-21. doi: 10.1016/j.remn.2011.12.002. Epub 2012 Mar 21. English, Spanish.

11.
12.

Molecular technology and the recombinant TSH have changed diagnostics of thyroid carcinoma with positive I-131 whole body scan but low serum thyroglobulin.

Montella L, Caraglia M, Abbruzzese A, Soricelli A, Prete SD, Squame G, Salvatore M.

Exp Mol Med. 2004 Jun 30;36(3):268-73.

13.

Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin.

van Tol KM, Jager PL, de Vries EG, Piers DA, Boezen HM, Sluiter WJ, Dullaart RP, Links TP.

Eur J Endocrinol. 2003 Jun;148(6):589-96.

15.

Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.

Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A.

J Clin Endocrinol Metab. 2002 Apr;87(4):1499-501.

PMID:
11932271
16.

[Diagnostic performance of serum thyroglobin and iodide-131 Na scan according to the type of recurrence in differentiated thyroid carcinoma].

Zafon C, Galofré P, Hernández C, Gemar E, Obiols B, Mesa J, Simó R.

Med Clin (Barc). 2000 Apr 8;114(13):487-90. Spanish.

PMID:
10846652
17.
20.

Endogenously labeled thyroid hormones (131I-T3/T4) in sera of patients with differentiated thyroid carcinoma.

Lukinac L, Franceschi M, Nöthig-Hus D, Lechpammer S, Tomasić J, Vranesić B, Pape E, Kusić Z.

Thyroid. 1996 Jun;6(3):201-6.

PMID:
8837327

Supplemental Content

Support Center